Much more than covid-19 is behind the biotech boom

Appetite for biopharma is on the rise as investors want to back scientific advances and the recession-proof sector, and generalist VCs don’t want to miss out on potential outsized returns.

DealsCoronavirusFeatured SliderHealthcareTechnology